Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial (Q34102430)

31 July 2017

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial (English)

1 reference

31 July 2017

1 reference

0 references

Michael Rud Lassen

1

1 reference

31 July 2017

Gary E Raskob

2

1 reference

31 July 2017

Alexander Gallus

3

1 reference

31 July 2017

Graham Pineo

4

1 reference

31 July 2017

Dalei Chen

5

1 reference

31 July 2017

Philip Hornick

6

1 reference

31 July 2017

ADVANCE-2 investigators

7

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

31 July 2017

1 reference

31 July 2017

375

1 reference

31 July 2017

9717

1 reference

31 July 2017

807-815

1 reference

Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962125-5

7 January 2021

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962125-5

7 January 2021

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962125-5

7 January 2021

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962125-5

7 January 2021

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962125-5

7 January 2021

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962125-5

7 January 2021

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962125-5

7 January 2021

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962125-5

7 January 2021

Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962125-5

7 January 2021

Apixaban or enoxaparin for thromboprophylaxis after knee replacement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962125-5

7 January 2021

Roentgen diagnosis of venous thrombosis in the leg

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962125-5

7 January 2021

Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962125-5

7 January 2021

The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962125-5

7 January 2021

Mantel-Haenszel-type tests for testing equivalence or more than equivalence in comparative clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962125-5

7 January 2021

Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962125-5

7 January 2021

Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962125-5

7 January 2021

Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962125-5

7 January 2021

Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962125-5

7 January 2021

10.1016/S0140-6736(09)62125-5

Identifiers

DOI

1 reference

31 July 2017

1 reference